Nyxoah S.A.
NYXH
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $162.1M
$1.62
▼ -7.95%
P/E
—
Mkt Cap
$162.1M
52-Wk Range
$1.26–$6.88
52-Week Range
$1.26 - $6.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 72.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary hypoglossal neurostimulation technology with CE-Mark approval
- Patient-centric design reducing treatment burden compared to CPAP alternatives
- Strong clinical evidence and differentiated therapeutic approach
- First-mover advantage in next-generation sleep apnea treatments
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
FDA approval pursuit and US market expansion
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.6% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NYXH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.67 vs -$0.47 consensus (-42.5% surprise). Revenue of $8.8M vs $8.6M expected (+1.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-42.5%
Revenue trend · last 8Q
—
—
-13%
+74%
+56%
+347%
+588%
+473%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.5M
$1.5M
$1.2M
$1.6M
$2.3M
$6.6M
$8.6M
$9.0M
Margins · last 8Q
Gross
—
Profit
-429.5%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 6, 2026
vs Industry
How NYXH stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.